CurifyLabs and APL collaborate to support critically ill patients with 3D printing medicine technology

Apotek Produktion & Laboratorier (APL), a major producer of extemporaneous medicines and a top CDMO in Sweden, has partnered with Finnish health tech company CurifyLabs to enhance medication administration for children and critically ill patients using innovative 3D printing technology.

Unlike traditional methods, 3D printing allows for more personalized dosages and forms with flexible shapes, leading to precise dosing and reduced side effects. APL’s conventional method produces 100 capsules per batch, but 3D printing will enable exact doses, minimizing waste and improving sustainability. This technology will also enhance workplace safety by reducing repetitive strain injuries and exposure to harmful substances.

APL plans to offer fully compliant 3D-printed extemporaneous medicines in Sweden by 2025, with the first printers arriving in September 2024. APL is a leading European manufacturer of extemporaneous drugs, while CurifyLabs specializes in personalized medicine solutions for pharmacies and hospitals, focusing on automated, cost-effective customization.